Company profile
Sorrento Therapeutics, Inc.
OTC: SRNE · Healthcare · Biotechnology
#408 of 1,422 Healthcare companies by revenue64th-percentile growth
EA Score
——FH —DQ 54GM —SS 63
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, workforce scale · ↓ filing timeliness, net margin
Methodology →Revenue TTM
$64.3M
Rev growth YoY (TTM)
+16.9%
Net income (FY)
-$572.8M
Employees
949
as of 2026-08-27
Market cap
$330.8k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$62.8M$62.8M2022
Net income-$572.8M-$572.8M2022
Operating income-$504.3M-$504.3M2022
Total assets$472.8M$472.8M2022
Liabilities$494.5M$494.5M2022
Equity-$18.6M-$18.6M2022
Revenue trend
FY2020 – FY2022 · USD
FY20
FY20
FY20
FY21
FY21
FY21
FY21
FY22
Revenue by segment
Filed disclosures · FY2022
By product
Product38%
Scilex Pharmaceuticals Inc Product Sales32%
Service15%
Sorrento Therapeutics, Inc. Product Revenues6%
Other Service Revenue5%
Service Drug And Reagants3%
By geography
Not disclosed.
The read
What is Sorrento Therapeutics, Inc.’s revenue?
Sorrento Therapeutics, Inc. booked $62.8M in FY2022 revenue, growing 19% year over year — faster than most Healthcare companies we track, at a -911.6% net margin.
Peers · Healthcare
Electromed, Inc.80B+Nuvation Bio Inc.49DDIH Holding US, Inc.——Tango Therapeutics, Inc.55CJourney Medical Corporation52DFortress Biotech, Inc.62CNeighbors
San Diego →Key facts
CEOHenry H. Ji
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeOTC: SRNE
Employees949
IPO date2007-01-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.